We employ a drug discovery and development approach that allows us to efficiently design, research and advance drug candidates as quickly and safely as possible. In just a couple of years, we have successfully advanced our lead PDC, CLR 131 into a Pivotal Trial for Waldenstrom’s macroglobulinemia as well as other Phase 1 and 2 clinical studies evaluating over ten disease indications. Additionally, we have initiated many collaborations and at least two proprietary programs that are rapidly progressing toward clinical studies.
Explore Our PipelineWith the challenges that have faced other targeted therapeutic approaches, we have focused on developing the next generation of targeted therapies leveraging our PLE platform technology. We combine knowledge of targeting specificity, uptake and intracellular trafficking, and novel linker chemistry and release mechanisms to allow both a greater diversity in warhead delivery and potentially greater efficacy.
View Our Technology
Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
F: 608-441-8121
investors@cellectar.com
LifeSci Advisors
Monique Kosse
Managing Director
T: 212-915-3820
monique@lifesciadvisors.com
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.